Collection 01 March 2021

Ovarian Cancer

March is Ovarian Cancer Awareness Month and in this Collection we highlight a selection of recent Reviews and research Articles published in BJC focusing on research into ovarian cancer, covering the epidemiology of ovarian cancer risk, insights into the cellular and molecular mechanisms underlying this cancer, experimental therapeutics and outcomes from clinical trials.

Editorials/ Comments

Cancer screening and prevention in BRCA mutation carriers: a missed opportunity?
- Nathalie LeVasseur
- Stephen Chia
Editorial7 Jun 2019 British Journal of Cancer
Is ovarian cancer surgery stuck in the dark ages?: a commentary piece reviewing surgical technologies
- David L. Phelps
- Srdjan Saso
- Sadaf Ghaem-Maghami
CommentOpen Access24 Aug 2020 British Journal of Cancer

Review

The untapped potential of ascites in ovarian cancer research and treatment
- Caroline Elizabeth Ford
- Bonnita Werner
- Kristina Warton
Review ArticleOpen Access8 May 2020 British Journal of Cancer

Consensus Statement

Expert recommendations on the management of hypertension in patients with ovarian and cervical cancer receiving bevacizumab in the UK
- Chris Plummer
- Agnieszka Michael
- Terry McCormack
Consensus StatementOpen Access11 Jun 2019 British Journal of Cancer

Articles

International trends in the uptake of cancer risk reduction strategies in women with a BRCA1 or BRCA2 mutation
- Kelly Metcalfe
- Andrea Eisen
- the Hereditary Breast Cancer Clinical Study Group
ArticleOpen Access11 Apr 2019 British Journal of Cancer
Phase 1 trial of olaparib and oral cyclophosphamide in BRCA breast cancer, recurrent BRCA ovarian cancer, non-BRCA triple-negative breast cancer, and non-BRCA ovarian cancer
- Chee Khoon Lee
- Clare Scott
- Michael Friedlander
ArticleOpen Access17 Jan 2019 British Journal of Cancer
Results of a phase II clinical trial of 6-mercaptopurine (6MP) and methotrexate in patients with BRCA-defective tumours
- Corran Roberts
- Victoria Y. Strauss
- Shibani Nicum
ArticleOpen Access9 Dec 2019 British Journal of Cancer
A multicentre, randomised, open-label, parallel-group Phase 2b study of belotecan versus topotecan for recurrent ovarian cancer
- Hee Seung Kim
- Sang-Yoon Park
- Yong Sang Song
ArticleOpen Access30 Sep 2020 British Journal of Cancer
Tumour-reactive T cell subsets in the microenvironment of ovarian cancer
- Marie Christine Wulff Westergaard
- Rikke Andersen
- Inge Marie Svane
ArticleOpen Access5 Feb 2019 British Journal of Cancer
Anti-VEGF therapy resistance in ovarian cancer is caused by GM-CSF-induced myeloid-derived suppressor cell recruitment
- Naoki Horikawa
- Kaoru Abiko
- Masaki Mandai
ArticleOpen Access14 Jan 2020 British Journal of Cancer
The RNA polymerase I transcription inhibitor CX-5461 cooperates with topoisomerase 1 inhibition by enhancing the DNA damage response in homologous recombination-proficient high-grade serous ovarian cancer
- Shunfei Yan
- Jiachen Xuan
- Keefe T. Chan
ArticleOpen Access11 Nov 2020 British Journal of Cancer
Tumour-associated neutrophils orchestrate intratumoural IL-8-driven immune evasion through Jagged2 activation in ovarian cancer
- Moran Yang
- Guodong Zhang
- Congjian Xu
ArticleOpen Access11 Aug 2020 British Journal of Cancer
Improved early detection of ovarian cancer using longitudinal multimarker models
- Harry J. Whitwell
- Jenny Worthington
- John F. Timms
ArticleOpen Access15 Jan 2020 British Journal of Cancer
Diagnosis of epithelial ovarian cancer using a combined protein biomarker panel
- Matthew R. Russell
- Ciaren Graham
- Robert L. J. Graham
ArticleOpen Access7 Aug 2019 British Journal of Cancer
Combining measures of immune infiltration shows additive effect on survival prediction in high-grade serous ovarian carcinoma
- Anne Montfort
- Rowan J. Barker-Clarke
- James D. Brenton
ArticleOpen Access6 Apr 2020 British Journal of Cancer
Clinical and pathological associations of PTEN expression in ovarian cancer: a multicentre study from the Ovarian Tumour Tissue Analysis Consortium
- Filipe Correia Martins
- Dominique-Laurent Couturier
- James D. Brenton
ArticleOpen Access18 Jun 2020 British Journal of Cancer
The mutational load and a T-cell inflamed tumour phenotype identify ovarian cancer patients rendering tumour-reactive T cells from PD-1⁺ tumour-infiltrating lymphocytes
- Diego Salas-Benito
- Enrique Conde
- Sandra Hervas-Stubbs
ArticleOpen Access5 Jan 2021 British Journal of Cancer
Biomarkers for site-specific response to neoadjuvant chemotherapy in epithelial ovarian cancer: relating MRI changes to tumour cell load and necrosis
- Jessica M. Winfield
- Jennifer C. Wakefield
- Nandita M. deSouza
ArticleOpen Access4 Jan 2021 British Journal of Cancer
Discovery of a biomarker candidate for surgical stratification in high-grade serous ovarian cancer
- Haonan Lu
- Paula Cunnea
- Christina Fotopoulou
Article21 Jan 2021 British Journal of Cancer
Genetic heterogeneity and evolutionary history of high-grade ovarian carcinoma and matched distant metastases
- Tariq Masoodi
- Sarah Siraj
- Khawla S. Al-Kuraya
ArticleOpen Access26 Feb 2020 British Journal of Cancer
Clinical relevance of TP53 hotspot mutations in high-grade serous ovarian cancers
- Musaffe Tuna
- Zhenlin Ju
- Gordon B. Mills
ArticleOpen Access29 Nov 2019 British Journal of Cancer
Activation of the reverse transsulfuration pathway through NRF2/CBS confers erastin-induced ferroptosis resistance
- Nan Liu
- Xiaoli Lin
- Chengying Huang
ArticleOpen Access10 Dec 2019 British Journal of Cancer
Ascites-derived ALDH+CD44+ tumour cell subsets endow stemness, metastasis and metabolic switch via PDK4-mediated STAT3/AKT/NF-κB/IL-8 signalling in ovarian cancer
- Yu-Xin Jiang
- Michelle Kwan-Yee Siu
- Karen Kar-Loen Chan
ArticleOpen Access11 May 2020 British Journal of Cancer
Sexually transmitted infections and risk of epithelial ovarian cancer: results from the Nurses’ Health Studies
- Renée T. Fortner
- Kathryn L. Terry
- Shelley S. Tworoger
ArticleOpen Access21 Mar 2019 British Journal of Cancer
Mendelian randomisation study of height and body mass index as modifiers of ovarian cancer risk in 22,588 BRCA1 and BRCA2 mutation carriers
- Frank Qian
- Matti A. Rookus
- on behalf of CIMBA
ArticleOpen Access19 Jun 2019 British Journal of Cancer

Ovarian Cancer

Editorials/ Comments

Cancer screening and prevention in BRCA mutation carriers: a missed opportunity?

Is ovarian cancer surgery stuck in the dark ages?: a commentary piece reviewing surgical technologies

Review

The untapped potential of ascites in ovarian cancer research and treatment

Consensus Statement

Expert recommendations on the management of hypertension in patients with ovarian and cervical cancer receiving bevacizumab in the UK

Articles

International trends in the uptake of cancer risk reduction strategies in women with a BRCA1 or BRCA2 mutation

Phase 1 trial of olaparib and oral cyclophosphamide in BRCA breast cancer, recurrent BRCA ovarian cancer, non-BRCA triple-negative breast cancer, and non-BRCA ovarian cancer

Results of a phase II clinical trial of 6-mercaptopurine (6MP) and methotrexate in patients with BRCA-defective tumours

A multicentre, randomised, open-label, parallel-group Phase 2b study of belotecan versus topotecan for recurrent ovarian cancer

Tumour-reactive T cell subsets in the microenvironment of ovarian cancer

Anti-VEGF therapy resistance in ovarian cancer is caused by GM-CSF-induced myeloid-derived suppressor cell recruitment

The RNA polymerase I transcription inhibitor CX-5461 cooperates with topoisomerase 1 inhibition by enhancing the DNA damage response in homologous recombination-proficient high-grade serous ovarian cancer

Tumour-associated neutrophils orchestrate intratumoural IL-8-driven immune evasion through Jagged2 activation in ovarian cancer

Improved early detection of ovarian cancer using longitudinal multimarker models

Diagnosis of epithelial ovarian cancer using a combined protein biomarker panel

Combining measures of immune infiltration shows additive effect on survival prediction in high-grade serous ovarian carcinoma

Clinical and pathological associations of PTEN expression in ovarian cancer: a multicentre study from the Ovarian Tumour Tissue Analysis Consortium

The mutational load and a T-cell inflamed tumour phenotype identify ovarian cancer patients rendering tumour-reactive T cells from PD-1⁺ tumour-infiltrating lymphocytes

Biomarkers for site-specific response to neoadjuvant chemotherapy in epithelial ovarian cancer: relating MRI changes to tumour cell load and necrosis

Discovery of a biomarker candidate for surgical stratification in high-grade serous ovarian cancer

Genetic heterogeneity and evolutionary history of high-grade ovarian carcinoma and matched distant metastases

Clinical relevance of TP53 hotspot mutations in high-grade serous ovarian cancers

Activation of the reverse transsulfuration pathway through NRF2/CBS confers erastin-induced ferroptosis resistance

Ascites-derived ALDH+CD44+ tumour cell subsets endow stemness, metastasis and metabolic switch via PDK4-mediated STAT3/AKT/NF-κB/IL-8 signalling in ovarian cancer

Sexually transmitted infections and risk of epithelial ovarian cancer: results from the Nurses’ Health Studies

Mendelian randomisation study of height and body mass index as modifiers of ovarian cancer risk in 22,588 BRCA1 and BRCA2 mutation carriers

Search

Quick links